Abstract
One of the most important advances in cancer research in recent years is the recognition that killing of tumor cells by anticancer therapies commonly used in the treatment of cancer, e.g. chemotherapy, γ-irradiation, immunotherapy or suicide gene therapy, is predominantly mediated by triggering cell death pathways including apoptosis in cancer cells. Thus, failure to undergo apoptosis may result in treatment resistance of cancers. Understanding the molecular events that regulate apoptosis in response to anticancer therapy and how cancer cells evade apoptotic cell death, provides novel perspectives for a more rational approach to develop molecular targeted therapies for combating cancer.
Keywords: Apoptosis, cancer, cancer therapy, resistance
Current Cancer Therapy Reviews
Title: Apoptosis Signaling Pathways in Anticancer Therapy
Volume: 4 Issue: 1
Author(s): Simone Fulda and Klaus-Michael Debatin
Affiliation:
Keywords: Apoptosis, cancer, cancer therapy, resistance
Abstract: One of the most important advances in cancer research in recent years is the recognition that killing of tumor cells by anticancer therapies commonly used in the treatment of cancer, e.g. chemotherapy, γ-irradiation, immunotherapy or suicide gene therapy, is predominantly mediated by triggering cell death pathways including apoptosis in cancer cells. Thus, failure to undergo apoptosis may result in treatment resistance of cancers. Understanding the molecular events that regulate apoptosis in response to anticancer therapy and how cancer cells evade apoptotic cell death, provides novel perspectives for a more rational approach to develop molecular targeted therapies for combating cancer.
Export Options
About this article
Cite this article as:
Fulda Simone and Debatin Klaus-Michael, Apoptosis Signaling Pathways in Anticancer Therapy, Current Cancer Therapy Reviews 2008; 4 (1) . https://dx.doi.org/10.2174/157339408783565510
DOI https://dx.doi.org/10.2174/157339408783565510 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacological Properties and Therapeutic Potential of Naringenin: A Citrus Flavonoid of Pharmaceutical Promise
Current Pharmaceutical Design CETUXIMAB: From Bench to Bedside
Current Cancer Drug Targets The Pro-Survival Function of Akt Kinase can be Overridden or Altered to Contribute to Induction of Apoptosis
Current Cancer Drug Targets The Important Role of Oncolytic Viruses in Common Cancer Treatments
Current Cancer Therapy Reviews Part II: Targeted Particles for Imaging of Anticancer Immune Responses
Current Drug Delivery ADAM8/MS2/CD156, an Emerging Drug Target in the Treatment of Inflammatory and Invasive Pathologies
Current Pharmaceutical Design The Chemopreventive and Chemotherapeutic Potentials of Tea Polyphenols
Current Pharmaceutical Biotechnology Cardiovascular-Active Venom Toxins: An Overview
Current Medicinal Chemistry Physiological and Pathological Functions of Acid-Sensing Ion Channels in the Central Nervous System
Current Drug Targets Meet Our Editorial Board Member
Clinical Cancer Drugs HSP60 as a Drug Target
Current Pharmaceutical Design Future Prospect of RNA Interference for Cancer Therapies
Current Drug Targets Human Cytomegalovirus US28: A Functionally Selective Chemokine Binding Receptor
Infectious Disorders - Drug Targets Benzamides as Melanotropic Carriers for Radioisotopes, Metals, Cytotoxic Agents and as Enzyme Inhibitors
Current Medicinal Chemistry Tumor Dormancy and the Angiogenic Switch: Possible Implications of Bone Marrow- Derived Cells
Current Pharmaceutical Design Identification and Characterization of Follistatin-Related Protein-1 Involved in the Regulation of Chinese Perch Skeletal Muscle Hyperplasia
Current Molecular Medicine Identification of Small Molecule Sulfonic Acids as Ecto-5'-Nucleotidase Inhibitors
Medicinal Chemistry Targeting EGFR in Pancreatic Cancer Treatment
Current Drug Targets Cyclin-Dependent Kinase as a Novel Therapeutic Target: An Endless Story
Current Chemical Biology MiRNAs in Human Cancers: The Diagnostic and Therapeutic Implications
Current Pharmaceutical Design